menu search

ITCI / Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q2 2022 Results - Earnings Call Transcript

Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q2 2022 Results - Earnings Call Transcript
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Juan Sanchez - Vice President, Corporate Communications and Investor Relations Sharon Mates - Chairman and Chief Executive Officer Mark Neumann - Executive Vice President and Chief Commercial Officer Suresh Durgam - Executive Vice President Chief Medical Officer Larry Hineline - Senior Vice President and Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Jessica Fye - JPMorgan Mike DiFiore - Evercore Brian Abrahams - RBC Capital Markets Charles Duncan - Cantor Fitzgerald Marc Goodman - SVB Karin Jenkins - Goldman Sachs Jason Gerberry - Bank of America Ash Verma - UBS Sumant Kulkarni - Canaccord Operator Good morning, ladies and gentlemen, and welcome to the Intra-Cellular Therapies' Second Quarter Earnings Call. At this time, all participants on a listen-only mode. Read More
Posted: Aug 9 2022, 14:25
Author Name: Seeking Alpha
Views: 110165

ITCI News  

Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised

By Zacks Investment Research
November 3, 2023

Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised

Intra-Cellular (ITCI) third-quarter 2023 earnings and revenues beat estimates. Caplyta sales continue to drive growth. more_horizontal

Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline

By Seeking Alpha
August 12, 2023

Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline

Intra-Cellular Therapies' main drug, Caplyta, has been successful in treating neuropsychiatric conditions and has shown potential in addressing mixed more_horizontal

Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised

By Zacks Investment Research
August 4, 2023

Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised

Intra-Cellular (ITCI) reports better-than-expected second-quarter results. Caplyta sales continue to drive growth. more_horizontal

Intra-Cellular Therapies: Depression Data Boosts Investment Prospects (Rating Upgrade)

By Seeking Alpha
May 25, 2023

Intra-Cellular Therapies: Depression Data Boosts Investment Prospects (Rating Upgrade)

Intra-Cellular's drug Caplyta (lumateperone) is advancing through trials for major depressive disorder (MDD), expanding its approved uses beyond schiz more_horizontal

Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?

By Zacks Investment Research
March 31, 2023

Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?

Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? more_horizontal

Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up

By Zacks Investment Research
March 29, 2023

Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up

Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. more_horizontal

Intra-Cellular (ITCI) Surges 16.4%: Is This an Indication of Further Gains?

By Zacks Investment Research
March 29, 2023

Intra-Cellular (ITCI) Surges 16.4%: Is This an Indication of Further Gains?

Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate re more_horizontal

Why Intra-Cellular Therapies Climbed Tuesday

By The Motley Fool
March 28, 2023

Why Intra-Cellular Therapies Climbed Tuesday

Caplyta, the company's lead drug, was responsible for most of the company's revenue in 2022. The potential addition of major depressive disorder to th more_horizontal


Search within

Pages Search Results: